Kimberly Blackwell's most recent trade in Monte Rosa Therapeutics Inc was a trade of 30,700 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics Inc | Kimberly L. Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Century Therapeutics Inc | Kimberly L. Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Century Therapeutics Inc | Kimberly L. Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Monte Rosa Therapeutics Inc | Kimberly L. Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 22,100 | 22,100 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Blackwell Kimberly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 250,000 | 504,800 | - | 0 | Common Stock | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.69 per share. | 01 Feb 2024 | 20,655 | 484,145 | - | 11.7 | 241,457 | Common Stock |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 10.29 per share. | 13 Nov 2023 | 5,000 | 254,800 | - | 10.3 | 51,448 | Common Stock |
| Century Therapeutics Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2023 | 44,000 | 44,000 | - | - | Stock Option (right to buy) | |
| Monte Rosa Therapeutics Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 20,500 | 20,500 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 355,200 | 355,200 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 244,800 | 249,800 | - | 0 | Common Stock | |
| Wag Group Co | Kimberly A. Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2022 | 107,143 | 107,143 | - | 0 | Restricted Stock Units | |
| Monte Rosa Therapeutics Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Century Therapeutics Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 19,872 | 19,872 | - | - | Stock Option (right to buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 1,708,809 | 1,708,809 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2022 | 427,202 | 427,202 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 1,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.80 per share. | 03 Jan 2022 | 1,000 | 6,000 | - | 47.8 | 47,800 | Common Stock |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Sale of securities on an exchange or to another person at price $ 83.74 per share. | 03 Jan 2022 | 1,000 | 5,000 | - | 83.7 | 83,740 | Common Stock |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Sale of securities on an exchange or to another person at price $ 81.84 per share. | 01 Dec 2021 | 1,000 | 5,000 | - | 81.8 | 81,840 | Common Stock |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2021 | 1,000 | 39,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.80 per share. | 01 Dec 2021 | 1,000 | 6,000 | - | 47.8 | 47,800 | Common Stock |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 1,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Sale of securities on an exchange or to another person at price $ 80.46 per share. | 01 Nov 2021 | 1,000 | 5,000 | - | 80.5 | 80,460 | Common Stock |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.80 per share. | 01 Nov 2021 | 1,000 | 6,000 | - | 47.8 | 47,800 | Common Stock |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 47.80 per share. | 25 Oct 2021 | 1,000 | 6,000 | - | 47.8 | 47,800 | Common Stock |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2021 | 1,000 | 41,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Sale of securities on an exchange or to another person at price $ 77.59 per share. | 25 Oct 2021 | 1,000 | 5,000 | - | 77.6 | 77,590 | Common Stock |
| Century Therapeutics Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 19,872 | 19,872 | - | - | Option (right to buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Zentalis Pharmaceuticals Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 5,000 | 5,000 | - | 0 | Common Stock | |
| Monte Rosa Therapeutics Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 47,132 | 47,132 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Kimberly Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2021 | 7,081 | 7,081 | - | - | Stock Option (Right to Buy) |